Table 4.

CDR3 nucleotide sequences of dominant peaks




CDR3 Sequences
Patient no.
VH
n1
DH
n2
JH
1   BAL   VH3 - 23   TGTGCGAAAG   CCTTGCGGC   GGATTACGATTTTTGGAGTGGGTAT   CGGGAAGGATGGGGG   CTTTGAGTACTGG   JH4  
  Tumor   VH3 - 23   TGTGCGAAAG   CCTTGCGGC   GGATTACGATTTTTGGAGTGGGTAT   CGGGAAGGATGGGGG   CTTTGAGTACTGG   JH4  
2   BAL   VH3 - 23   TGTGCGAAA   TTGGTG   GGAGGCAGCTGCT   CTCTCCCG   TGTGAATACTGG   JH4  
  Tumor   VH3 - 23   TGTGCGAAA   TTGGTG   GGAGGCAGCTGCT   CTCTCCCG   TGTGAATACTGG   JH4  
3   BAL   VH*  TGTGCGAGAGA   CTTCTCGGGTCCTCCA   AGTGGGAGCTAC   C   TCTACTACTGG   JH4  
  Tumor   VH*  TGTGCGAGAGA   CTTCTCGGGTCCTCCA   AGTGGGAGCTAC   C   TCTACTACTGG   JH4  
4   BAL   VH3 - 15   TGTACCACAGA   TCCGCTTG   ATTACGATTTTTGGAGTGG   CGGT   TACTACAACTCCATGGACGTCTGG   JH6  
  Tumor   VH3 - 15   TGTACCACAGA   TCCGCTTG   ATTACGATTTTTGGAGTGG   CGGT   TACTACAACTCCATGGACGTCTGG   JH6  
5   BAL   VH3 - 30   TGTGCGAGAGA    AGGATATTTTGACTGGTTATT   TGCGCAACTCTTTGGCCCA   TTTGACTGCTGG   JH4  
  Tumor   VH3 - 30   TGTGCGAGAGA    AGGATATTTTGACTGGTTATT   TGCGCAACTCTTTGGCCCA   TTTGACTGCTGG   JH4  
6   BAL   VH*  TGTGCGAGAGA   T   CATCTGCGGGGAC   G   TGTCTTTGATGTCTGG   JH3  
  Tumor   VH*  TGTGCGAGAGA   T   CATCTGCGGGGAC   G   TGTCTTTGATGTCTGG   JH3  
7   BAL   VH3 - 7   TGTGCGAGA   GGAA   TTCGGAGTGATGA   CGGTCTTAGTGGAGGGGCAA   TGGACGTCTGG   JH3  
8   BAL   VH5 - 51   TGTGCGAGA   ACGA   AATACGGTTACAACTC   GG   ACGGTATGGACGTCTGG   JH6  
9   BAL   VH5 - a03   TGTGCGAGA    GTGGTACCAGCTGATAT   AGTCGGGAT   CTACTACTACGCTTTGGACGTCTGG   JH6  
10
 
BAL
 
VH3 - 13
 
TGTGCAAGAG
 
GA
 
TATTACTATGCTTCGGGGAGTT
 
TGG
 
TTGACTACTGG
 
JH4
 



CDR3 Sequences
Patient no.
VH
n1
DH
n2
JH
1   BAL   VH3 - 23   TGTGCGAAAG   CCTTGCGGC   GGATTACGATTTTTGGAGTGGGTAT   CGGGAAGGATGGGGG   CTTTGAGTACTGG   JH4  
  Tumor   VH3 - 23   TGTGCGAAAG   CCTTGCGGC   GGATTACGATTTTTGGAGTGGGTAT   CGGGAAGGATGGGGG   CTTTGAGTACTGG   JH4  
2   BAL   VH3 - 23   TGTGCGAAA   TTGGTG   GGAGGCAGCTGCT   CTCTCCCG   TGTGAATACTGG   JH4  
  Tumor   VH3 - 23   TGTGCGAAA   TTGGTG   GGAGGCAGCTGCT   CTCTCCCG   TGTGAATACTGG   JH4  
3   BAL   VH*  TGTGCGAGAGA   CTTCTCGGGTCCTCCA   AGTGGGAGCTAC   C   TCTACTACTGG   JH4  
  Tumor   VH*  TGTGCGAGAGA   CTTCTCGGGTCCTCCA   AGTGGGAGCTAC   C   TCTACTACTGG   JH4  
4   BAL   VH3 - 15   TGTACCACAGA   TCCGCTTG   ATTACGATTTTTGGAGTGG   CGGT   TACTACAACTCCATGGACGTCTGG   JH6  
  Tumor   VH3 - 15   TGTACCACAGA   TCCGCTTG   ATTACGATTTTTGGAGTGG   CGGT   TACTACAACTCCATGGACGTCTGG   JH6  
5   BAL   VH3 - 30   TGTGCGAGAGA    AGGATATTTTGACTGGTTATT   TGCGCAACTCTTTGGCCCA   TTTGACTGCTGG   JH4  
  Tumor   VH3 - 30   TGTGCGAGAGA    AGGATATTTTGACTGGTTATT   TGCGCAACTCTTTGGCCCA   TTTGACTGCTGG   JH4  
6   BAL   VH*  TGTGCGAGAGA   T   CATCTGCGGGGAC   G   TGTCTTTGATGTCTGG   JH3  
  Tumor   VH*  TGTGCGAGAGA   T   CATCTGCGGGGAC   G   TGTCTTTGATGTCTGG   JH3  
7   BAL   VH3 - 7   TGTGCGAGA   GGAA   TTCGGAGTGATGA   CGGTCTTAGTGGAGGGGCAA   TGGACGTCTGG   JH3  
8   BAL   VH5 - 51   TGTGCGAGA   ACGA   AATACGGTTACAACTC   GG   ACGGTATGGACGTCTGG   JH6  
9   BAL   VH5 - a03   TGTGCGAGA    GTGGTACCAGCTGATAT   AGTCGGGAT   CTACTACTACGCTTTGGACGTCTGG   JH6  
10
 
BAL
 
VH3 - 13
 
TGTGCAAGAG
 
GA
 
TATTACTATGCTTCGGGGAGTT
 
TGG
 
TTGACTACTGG
 
JH4
 

Underlined nucleotides are mutated when compared with the more homologous germline segment.

*

VH nucleotide sequence was too short for the assessment of the more homologous VH germline segment.

or Create an Account

Close Modal
Close Modal